Literature DB >> 34765291

Dysregulation and activities of ubiquitin specific peptidase 2b in the pathogenesis of hepatocellular carcinoma.

Christina Nadolny1, Xinmu Zhang1, Qiwen Chen1, Syed F Hashmi1, Winifer Ali1, Christopher Hemme1, Nagib Ahsan2,3,4, Yuan Chen1, Ruitang Deng1.   

Abstract

Ubiquitin specific peptidase-2 (USP2) plays important roles in a myriad of cellular activities through deubiquitinating target proteins and its implications in various diseases, especially cancers, are starting to emerge. Our current understanding on USP2 expression in subjects with hepatocellular carcinoma (HCC) and its roles in the pathogenesis of HCC is limited. In this study, we found that USP2 protein and mRNA levels were significantly dysregulated in HCC tumor (HCC-T) when compared to adjacent non-tumor (HCC-NT) or normal liver tissues from both human and mouse HCC model. Among the USP2 isoforms, USP2b was the predominant isoform in the normal liver and markedly down-regulated in HCC-T tissues in both human and mice. Data from overexpression, chemical inhibition and knockout studies consistently demonstrated that USP2b promoted cell proliferation, colony formation and wound healing in HepG2 and Huh 7 cells. On the other hand, USP2b exhibited proapoptotic and pronecrtotic activities through enhancing bile acid-induced apoptosis and necrosis in both HepG2 and Huh 7 cells. Unbiased proteomic analysis of USP2-knockout (KO) and parental HepG2 cells resulted in identification of USP2-regulated downstream target proteins involved in cell proliferation, apoptosis, and tumorigenesis, including serine/threonine kinase 4 (STK4), epidermal growth factor receptor (EGFR), dipeptidyl peptidase 4 (DPP4) and fatty acid binding protein 1 (FABP1). In conclusion, USP2b expression was dysregulated in subjects with HCC and contributed to the pathogenesis of HCC by promoting cell proliferation and exerting proapoptotic and pronecrotic activities. The findings provide the molecular basis for developing therapies for HCC through modulating USP2b expression or activities. AJCR
Copyright © 2021.

Entities:  

Keywords:  HCC pathogenesis; USP2b dysregulation; apoptosis and necrosis; cell proliferation; ubiquitination and deubiquitination

Year:  2021        PMID: 34765291      PMCID: PMC8569343     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  70 in total

1.  Endogenous bile acids as carcinogens.

Authors:  Peter L M Jansen
Journal:  J Hepatol       Date:  2007-06-14       Impact factor: 25.083

2.  Ubiquitin-specific protease 2a promotes hepatocellular carcinoma progression via deubiquitination and stabilization of RAB1A.

Authors:  Bin Xiong; Junwei Huang; Yan Liu; Min Zou; Zhibo Zhao; Jianping Gong; Xiaoling Wu; Chan Qiu
Journal:  Cell Oncol (Dordr)       Date:  2020-10-19       Impact factor: 6.730

3.  Bile acids promote diethylnitrosamine-induced hepatocellular carcinoma via increased inflammatory signaling.

Authors:  Lina Sun; Kevin Beggs; Prachi Borude; Genea Edwards; Bharat Bhushan; Chad Walesky; Nairita Roy; Michael W Manley; Sumedha Gunewardena; Maura O'Neil; Hua Li; Udayan Apte
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-05-05       Impact factor: 4.052

4.  The ubiquitin-specific protease USP2a prevents endocytosis-mediated EGFR degradation.

Authors:  Z Liu; S M Zanata; J Kim; M A Peterson; D Di Vizio; L R Chirieac; S Pyne; M Agostini; M R Freeman; M Loda
Journal:  Oncogene       Date:  2012-06-18       Impact factor: 9.867

5.  Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Chunmei Wang; Coral Ho; Sara Ladu; Susie A Lee; Sandra Mattu; Giulia Destefanis; Salvatore Delogu; Antje Zimmermann; Johan Ericsson; Stefania Brozzetti; Tommaso Staniscia; Xin Chen; Frank Dombrowski; Matthias Evert
Journal:  Gastroenterology       Date:  2010-12-11       Impact factor: 22.682

Review 6.  Recent insights into the biological functions of liver fatty acid binding protein 1.

Authors:  GuQi Wang; Herbert L Bonkovsky; Andrew de Lemos; Frank J Burczynski
Journal:  J Lipid Res       Date:  2015-10-06       Impact factor: 5.922

7.  Overexpression of ubiquitin-specific protease 2a (USP2a) and nuclear factor erythroid 2-related factor 2 (Nrf2) in human gliomas.

Authors:  Mohammad Reza Boustani; Reza Jalili Khoshnood; Fermoozan Nikpasand; Zabihollah Taleshi; Koorosh Ahmadi; Emad Yahaghi; Peyman Karimi Goudarzi
Journal:  J Neurol Sci       Date:  2016-03-02       Impact factor: 3.181

Review 8.  Two Sides of the Same Coin - Compensatory Proliferation in Regeneration and Cancer.

Authors:  Neha Diwanji; Andreas Bergmann
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 9.  Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think.

Authors:  Camille Lobry; Philmo Oh; Iannis Aifantis
Journal:  J Exp Med       Date:  2011-09-26       Impact factor: 14.307

Review 10.  The Two Sides of YY1 in Cancer: A Friend and a Foe.

Authors:  Sailu Sarvagalla; Srinivasa Prasad Kolapalli; Sivakumar Vallabhapurapu
Journal:  Front Oncol       Date:  2019-11-20       Impact factor: 6.244

View more
  2 in total

Review 1.  Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Authors:  Jie Zhao; Jinhui Guo; Yanan Wang; Qiancheng Ma; Yu Shi; Feng Cheng; Qiliang Lu; Wen Fu; Guangxiong Ouyang; Ji Zhang; Qiuran Xu; Xiaoge Hu
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

2.  Aberrant expression of GSTM5 in lung adenocarcinoma is associated with DNA hypermethylation and poor prognosis.

Authors:  Xuewei Hao; Jun Zhang; Guoyou Chen; Weiwei Cao; Hongyang Chen; Shuo Chen
Journal:  BMC Cancer       Date:  2022-06-21       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.